UAE ONCOLOGY Drugs Market

1. UAE ONCOLOGY DRUGS MARKET

2. As the economy and population of the UAE grows the number of cancer patients will also significantly increase INNOVATION & DATA Population (65+ years) Total Cancer Incidence Total Cancer Mortality Probability of Premature death in 2030 603 27 0.7% Number of clinical trials (1999-2022) 173K (2022) 643K (2040) 4.8K (2020) 15.9K (2040) 1.9K (2020) 8.2K (2040) 4.5% (2020) 2.6% (SDG*) Total number of clinical trials for oncology (2022) Projected to miss SDG target by Research & development (R&D) expenditure (% of GDP) 272% 231% 335% 1.86% TOP 3 CANCERS: INCIDENCE ESTIMATIONS TOP 3 CANCERS: MORTALITY ESTIMATIONS 2020 2040 2020 2040 + 123% 969 +418% +371% 2306 +188% +310% 674 641 1372 +74.3% 1030 706 222 187 143 405 334 Breast Thyroid Colon Beast Traches, bronchus & lung (TBL) Colon SDG – Sustainable Development Goals

3. UAE ONCOLOGY DRUG MARKET FORECAST, 2020-2028 (in $ Mn) 3000.0 MARKET SIZE & FORECAST $2,540.0 2500.0 $2,254.9 CAGR-12.6% $1,577.7 $2,001.9 2000.0 The UAE Oncology Drugs Market, valued at $1.243 Bn in 2022, is expected to grow significantly, reaching $2.540 Bn by 2028, with a projected CAGR of 12.6% throughout the forecast period $1,777.2 $1,400.6 1500.0 $1,243.4 $1,103.9 $980.0 1000.0 500.0 0.0 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F

4. MARKET OVERVIEW METASTATIC CANCER DRUGS MARKET COLORECTAL CANCER DRUGS MARKET MEA: Metastatic Cancer Drugs Market ($ Mn, 2021) MEA: Colorectal Cancer Market Share (2022) 27.3% 27.2% 27.2% 18.3% 21.8% 1127.0 839.1 721.6 Saudi Arabia 3ʳᵈ Rest of MEA UAE South Africa 622.3 2ⁿᵈ Most common cause for cancer deaths in UAE (8.9% of total) Leading cause of cancer deaths worldwide Saudi Arabia Rest of MEA UAE South Africa Market for colorectal cancer in the UAE poses several growth opportunities such as rising incidence of colon cancer among young population (Youngest person diagnosed from CRC is 16 years) UAE ranks 1ˢᵗ among MENA countries in attracting multinational companies in Pharma Industry in 2022 UAE covers 21.8% of Middle East & Africa Metastatic Cancer Drug Market Due to lack of awareness about CRC, market might hinder the growth (Government implemented CRC screening programs in 2018)

5. DRIVERS AND RESTRAINTS MARKET DRIVERS: MARKET RESTRAINTS: Rising Number of New Cancer Cases: With metastatic cancer causing up to 90% of cancer deaths, are a major concern in the UAE. There is also a significant gender disparity, with 51.3% of cases in women High Cost of Oncology Drugs: Price barriers limit market penetration, reducing the patient pool. With monthly chemotherapy costs up to Dh32,000 ($8712), pricing strategies and healthcare reforms are needed for market sustainability Cancer Screening & Support Programs : The UAE government offers free nationwide breast cancer screenings through the IFHAS program in Abu Dhabi since June 2022. It provides periodic screenings for Thiqa cardholders aged 18+ for breast, colorectal, cervical, and lung cancers Limited Clinical Trials: Limited clinical trials in the UAE hinder the development of innovative oncology drugs, reducing treatment options and affecting patient outcome Shortages of Healthcare Providers: Healthcare provider shortages in the UAE, with Abu Dhabi facing a projected shortfall of 11,000 nurses and 5,000 allied health professionals by 2030, may lead to reduced quality of oncology treatments UAE Drug Approval Process: The UAE excels globally in rapid drug approvals, especially for cancer treatments, often approving new medicines in less than six months, often shortly after FDA clearance

6. KEY PLAYERS